Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 11
Submit an article Journal homepage
249
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma

Eva Duvalyana School of Medicine, University of California, San Francisco, CA, USAORCID Iconhttps://orcid.org/0009-0005-5132-6750View further author information
ORCID Icon,
Nina Shahb Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USAView further author information
,
Mimi Loc Department of Pharmaceutical Services, University of California, San Francisco, CA, USAView further author information
,
Thomas Martin IIIb Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USAView further author information
,
Jeffrey L. Wolfb Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USACorrespondence[email protected]
View further author information
,
Alfred Chungb Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USAView further author information
,
Shagun Arorab Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USAView further author information
,
Chiung-Yu Huangd Department of Epidemiology & Biostatistics, University of California, San Francisco, CA, USAView further author information
&
Sandy W. Wongb Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USAView further author information
 show all
Pages 1888-1891 | Received 18 May 2023, Accepted 20 Jul 2023, Published online: 21 Aug 2023
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

E.D., S.A., and C.Y.H report that there are no competing interests to declare. M. L. is a consultant for EUSA Pharma and Oncopeptides. T.M. receives research funding from Janssen, Amgen, and Sanofi. T.M. is a consultant for GlaxoSmithKline. J.W. is a consultant for Adaptive Biotechnologies, Teneobio, Sanofi, and Amgen. A.C. receives research funding from Caelum. N.S. receives research funding from Bluebird Bio, BMS/Celgene, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and Teneobio. N.S. is a consultant for Amgen, CareDx, CSL Behring, GSK, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, and Sanofi. S.W.W receives research funding from Bristol-Myers Squib, Fortis, Janssen, Genentech, GSK, and Caelum. S.W.W. is on the advisory board for Sanofi and Telix. S.W.W. is a consultant for Amgen.

Additional information

Funding

This study was supported by the University of California, San Francisco School of Medicine (Summer Explore Research Grant) and the UCSF Multiple Myeloma Translational Initiative.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.